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Introduction:  Small  area  variations  in  healthcare  infrastructure  may  result  in  differences  in
early  detection  and  outcomes  for patients  with  rare  diseases.
Methods:  It  is our  aim  to  provide  a  framework  for evaluating  small  area  variations  in health-
care infrastructure  on  the diagnostics  and  health  outcomes  of rare diseases.  We  focus  on
administrative  data  as  it allows  (a)  for relatively  large  sample  sizes  even  though  the  preva-
lence  of  rare  diseases  is  very  low,  and  (b)  makes  it  possible  to  link  information  on  healthcare
infrastructure  to  morbidity,  mortality,  and  utilization.
Results:  For  identifying  patients  with  a  rare  disease  in  a database,  a combination  of  differ-
ent classiﬁcation  systems  has  to  be used due  to usually  multiple  diseases  sharing  one  ICD
code.  Outcomes  should  be chosen  that  are (a) appropriate  for  the  disease,  (b)  identiﬁable
and  reliably  coded  in the  administrative  database,  and  (c)  observable  during  the  limited
time period  of  the follow-up.  Risk  adjustment  using  summary  scores  of  disease-speciﬁc  or
comprehensive  risk  adjustment  instruments  might  be preferable  over  empirical  weights
because  of the  lower  number  of  variables  needed.
Conclusion:  The  proposed  framework  will  help  to  identify  differences  in  time  to  diagnosis
and  treatment  outcomes  across  areas  in  the  context  of rare  diseases.
 . Introduction
The provision of adequate care for rare diseases, i.e.
iseases with prevalence below 5/10,000 inhabitants [1],
oses additional problems compared to common diseases.
he low prevalence and the high number of different rare
iseases create a complex and demanding environment
ithin which physicians must detect possible symptoms
nd ﬁnd suitable treatment alternatives. Because of their
ow prevalence, the disease-speciﬁc combinations of symp-
oms are not part of the physician’s daily diagnostic and
herapeutic activities. This is why rare diseases are often
ot detected under routine care conditions: diagnosis and
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treatment of rare diseases thus requires a higher degree of
knowledge and specialization.
It is often assumed that the existence of an excel-
lent healthcare infrastructure in a given area is likely to
improve diagnostic quality, thereby allowing early detec-
tion of the disease and so improving long-term prognosis.
With respect to various common diseases, there is a long
tradition – stretching back to the 1970s – of research on
small area variations, i.e. differences in the rates of use
of medical services, especially regarding practice patterns
[2,3]. Phelps found that small area variations are likely to be
associated with welfare losses [4].  However, the effects of
small area variations in healthcare infrastructure on early
Open access under CC BY-NC-ND license.detection and health outcomes for rare diseases have so far
not been evaluated.
A review of existing literature revealed that several
methodological aspects have been dealt with separately
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and only in the context of common diseases. It is thus
the aim of this article to provide a comprehensive frame-
work for evaluating small area variations in healthcare
infrastructure on the diagnostics and health outcomes of
rare diseases. As rare diseases are often complex, chronic
and require integrated care across sectors, studies must be
able to follow patients along the care pathway over time.
Therefore, we focus on administrative data. It allows for
relatively large sample sizes even though the prevalence of
rare diseases is very low. It also makes it possible to link
information on the availability of healthcare infrastructure
to data on morbidity, mortality, and healthcare utilization
across different sectors.
Following the introduction, in Section 2 we  outline
study designs that allow us to measure the time between
the ﬁrst symptom of a rare disease and its ﬁrst diagno-
sis. We  structure this section along the main challenges for
deﬁning the study design. We  describe different methods
for identifying patients with a rare disease or its symp-
toms in administrative data through the use of diagnoses,
procedure codes, reimbursement codes, ATC codes, or a
combination of those, and taking into account data qual-
ity. We  also describe the study setting to analyse delay in
diagnosis and treatment outcomes and present a concep-
tualization of healthcare infrastructure within the ambit of
this research. Section 3 addresses the adaption of disease-
speciﬁc or comprehensive risk adjustment methods to
rare diseases using administrative data, e.g. the Charl-
son Comorbidity Index or the Elixhauser Score. Section
4 proposes statistical methods to measure the effect of
healthcare infrastructure on diagnostics and outcomes in
the context of rare diseases. The ﬁnal section addresses pos-
sible health policy implications based on studies which use
this framework.
2. Choice of study design
Because of their low prevalence as well as their high
complexity, rare diseases present a challenge not only
for the healthcare system, but also for research based on
administrative data. From the researcher’s viewpoint, the
rarity may  result in a low number of observations. Thus, any
administrative database accessed for retrospective analysis
needs to be large. We  propose the following study design
based on administrative data for evaluating whether spe-
cial regional characteristics facilitate early diagnosis of rare
diseases or improve outcomes after treatment.
2.1. Identiﬁcation of a patient with a rare disease in
administrative data
The identiﬁcation of patients in an administrative
database is usually accomplished by searching for diag-
noses related to in- or outpatient care episodes that identify
the disease according to the International Classiﬁcation of
Diseases [ICD]. Ideally, this would require a prior valida-
tion of the criteria with respect to the database that is used
[5].  This is because the reliability of coded ICDs primar-
ily depends on the coding requirements imposed on the
providers by the healthcare system, as well as the vari-
ability in disease coding systems themselves, i.e. ICD-10 vs.Fig. 1. Measuring delay in diagnosis.
ICD-9, and on the data-handling process between physician
and database [6].
If detailed coding is a prerequisite for reimbursement, as
it is in case of inpatient hospital stays reimbursed through
DRGs [7],  the occurrence of a single ICD code for a dis-
ease can be considered sufﬁcient to identify a patient [8].
If detailed coding is not a prerequisite for reimbursement,
as for example in the case of outpatient physician contacts
reimbursed through lump sum payments, at least one fur-
ther diagnosis relating to the disease within 180 days or
360 days should be required to validate the ﬁrst diagno-
sis. Rare diseases are often hidden in ICD codes of other
rare or common diseases. In such cases, researchers have
to look carefully for alternatives and may  have to com-
bine different ICD codes. Combinations of ICD codes and
prescription records or – if available – procedure codes
can also be used and might outperform identiﬁcation by
ICD only [6,9]. In any case, for very rare diseases, a com-
bination of different classiﬁcation systems has to be used
due to multiple diseases sharing one ICD code. For some
diseases, e.g. osteonecrosis [10], the use of administra-
tive databases alone is not sufﬁcient to identify patients
because the respective ICD codes covers many similar dis-
eases and researchers can only identify the disease when
additional information from clinical records is taken into
account. Thus administrative databases may  have to be
combined with a review of medical records. It should also
be considered that for some rare diseases undercoding and
resulting reporting bias may  be a problem, because physi-
cians may  not know or use the appropriate codes for certain
rare diseases.
2.2. Study setting to analyse delay in diagnosis and
treatment outcomes
Delay in diagnosis can be further differentiated into
delay by patients, i.e. the time between the onset of symp-
toms and time of ﬁrst medical contact, and delay by
providers, i.e. the time between the ﬁrst medical consul-
tation and start of treatment [11]. Delay by patients cannot
be observed if administrative data alone is used. Once a
patient with a rare disease has been identiﬁed, however,
delay by providers can be best approximated by the num-
ber of days between the occurrence of the ﬁrst symptom
that is characteristic for the disease in the database and
the date the patient is diagnosed (see Fig. 1). For most rare
diseases, the date of the ﬁrst diagnosis will also mark the
start of treatment, or treatment will at least start shortly
afterwards.
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Accessing symptoms in databases and linking them to
elay in diagnosis has already been used in many areas [12],
ncluding breast cancer [11], gynecological malignancies
13], chronic lymphocytic leukemia [14], and tuberculosis
15]. Kalkbrenner et al. used a similar approach in mea-
uring the impact of health services accessibility at birth
n the delay in diagnosis for autism [16]: medical records
f children that met  surveillance criteria for autism spec-
rum diagnosis by the age of eight were analysed for the
ime between birth and the ﬁrst diagnosis of autism. Care
ust be taken in identifying the appropriate symptoms
or a disease as the symptoms have to be (a) appropri-
te for the disease, and (b) identiﬁable and reliably coded
n the administrative database. A literature review and/or
referably also expert opinion should be used. In addition,
 sensitivity analysis using the second symptom that is
haracteristic for the rare disease should be performed.
Once a patient has been diagnosed, one may  follow
p the patient from the day of diagnosis whilst measur-
ng intermediary outcomes, i.e. known complications of
he disease, healthcare utilization, costs and/or mortality.
otential outcomes should be identiﬁed using literature
eview and/or expert opinion. Care should be taken in
hoosing outcomes that are (a) appropriate for the disease,
b) identiﬁable and reliably coded in the administrative
atabase, and (c) observable during the limited time period
f the follow-up. For example, mortality may  be an appro-
riate outcome for Marfan’s Syndrome that is reliably
oded and can be identiﬁed in administrative databases.
iven a limited observational period of one or two years, it
an, however, not be observed.
.3. Conceptualizing healthcare infrastructure
In their literature review, McLaughlin et al. differenti-
te between small-area variations studies, where areas are
eﬁned as aggregates of zip codes, and regional variations
tudies, deﬁned as large geopolitical or health service areas
17]. The population size of what is counted as an area
aries according to whether it is rural or urban. Wennberg
nd Gittelsohn, in their comparison of utilization and
esources of healthcare facilities in Vermont, deﬁned areas
s towns or townships that surrounded a hospital, ranging
etween 7960 inhabitants per area to 109,750 inhabitants
er area [2];  whilst Gittelsohn and Powe, analysing vari-
tion in hospital utilization in Maryland, grouped postal
ode areas by contiguity, ranging between 53,000 inhabi-
ants per area to 1,433,000 inhabitants per area [18].
To measure the impact of healthcare infrastructure on
elay in diagnosis, the local availability of care is more
ikely than the regional availability of health services to
ave an impact, since patients will ﬁrst consult their local
outpatient) care providers before traveling to a provider
pecialised on a disease they have not yet been diagnosed
or. This is particularly true for densely populated areas.
hus, when measuring the impact of healthcare infras-
ructure on delay in diagnosis, we recommend the use of
ggregate postal code regions around the patient’s resi-
ence that lie within a one to one-and-a-half hour travel
istance. In addition, however, the expected number ofolicy 105 (2012) 110– 118
cases in an area has to be taken into account in order to
produce valid results.
For availability of healthcare infrastructure, possible
measures are physician density subdivided by specialty,
and the quantity of diagnostic equipment such as MRI, CT,
or PET/CT scanners. Density should be deﬁned by number
per square kilometer or square mile rather than per inhab-
itant. This is because density per square kilometer serves
as a better proxy for availability/access, whereas density
per inhabitant also includes the comfort factor waiting
times for an appointment. For some diseases, distance to
an emergency department may  also represent an impor-
tant characteristic facilitating early diagnosis or improved
treatment outcomes. Distance between residence and a
highly specialised care facility may  also explain delay in
diagnosis, as knowledge transfer from a highly specialised
(inpatient) provider to other (outpatient) providers might
only occur if they are in close proximity to each other and
interact regularly.
When analysing treatment outcomes for rare diseases
after diagnosis, the deﬁnition of area primarily depends
on the disease and its requirements. For some diseases
there will be one main – potentially highly specialised
– health care provider to the patient. Patients with rare
diseases often have to travel more than 100 km,  several
times a year, for treatment in a specialised outpatient or
inpatient facility. Thus it is important to measure the char-
acteristics of the main provider even if it is far away from
the patient’s residence. In addition, as already mentioned
the local supporting healthcare infrastructure in the area
around residence as deﬁned above should be measured.
The study design proposed here requires a longitudinal
follow-up before and/or after diagnosis of the rare disease.
Thus, change of residence needs to be controlled for. This
is of particular importance (a) if only the current address
is obtained but not the residence history [18], e.g. due to
issues of data protection, or (b) if a time lag is to be expected
between the actual change of residence and the integration
of the updated information into the database. Treatment in
a region that is different from the observed area of resi-
dence might occur for various reasons, with change in the
actual area of residence being only one of them. An insured
person may  live in one (postal code) area whilst working in
another area. Also, a neighboring, more urban area might
be preferred in seeking care because of higher availabil-
ity and greater specialization of providers [18]. If an actual
change in residence occurred, the insured person should
be excluded from the analysis or the observation should
be treated as censored after change of residence. If care
is regularly accessed in two areas, either (a) the deﬁni-
tion of areas should be critically reconsidered (especially
if a high number of insured persons is affected), or (b) the
insured person should be excluded from the analysis. If,
however, only a temporary change in the area where care
is accessed occurs, e.g. due to care being accessed whilst on
vacation, the insured person should not be excluded from
the analysis.The area of residence or the area where the patient
accessed care most frequently in a period can be used in
an algorithm that allows for a temporary change in access
to care (e.g. due to being on vacation in another area)
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Fig. 2. Algorithm to control for change in residence or in area where care has been accessed most frequently.
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hilst detecting permanent change. For each period t, the
rea code of the area where care has been accessed most
n period t is compared with the area codes of the area
here care has been accessed most in periods t + 2 and t + 3,
espectively. Only if the both comparisons yield the same
ifference compared to period t, has a permanent change of
esidence taken place. In the example in Fig. 2, the patient
as changed the area where care is accessed most in period
, whilst having been on vacation in another area in period
. In period 2, the area codes where care has been accessed
ost frequently yields differences compared to periods 4
nd 5. However differences are not the same. Thus the algo-
ithm would conclude that the patient did not change the
rea where care is accessed most frequently (area of resi-
ence). In period 3, however, comparison between period 3
nd periods 5 and 6 yield the same differences in area codes.
hus, a change in the area where care has been accessed
ost frequently has taken place.
. Adaption of disease-speciﬁc or comprehensive
isk adjustment methods
Risk adjustment is an important prerequisite for
oth research questions namely, delay in diagnosis and
reatment outcomes due to differences in healthcare infras-
ructure. Co-morbidities might lead to a higher frequency
f contacts with the healthcare system. Thus more severe
ymptoms might be detected earlier whilst less severe
ymptoms may  remain masked by other conditions.
The literature contains various proposals for risk scores
hat make use of secondary diagnoses and/or prescription
ata to predict outcomes such as mortality. In the absence
f other instruments, they have also been used to predict
ength of stay, costs, or other outcomes. The basic idea is
o classify comorbidities into predeﬁned groups. In turn,
he variables for each group of comorbidities are used as
ontrols in a regression framework. For most instruments,
 summary score that applies pre-deﬁned weights for each
omorbidity group can be used instead.
The Charlson Comorbidity Index, for example, was
eveloped to provide a taxonomy for comorbidities to pre-
ict 1-year mortality after an inpatient stay. The original
ersion proposed a summary score based on 19 comor-
idity groups [19]. Deyo et al. established and validated
 coding algorithm for use with administrative data that
ontained 17 comorbidity groups deﬁned according to
CD-9-CM [20]. An adaption of the comprehensive risk
djustment score to ICD-10-AM was provided by Sun-
ararajan et al. [21].
The Elixhauser Score, as another comprehensive risk
djustment instrument, was originally deﬁned to predict
ospital costs, length of stay and in-hospital mortality.
he score resulted in a set of 30 comorbidities, originally
oded according to ICD-9-CM [22]. An ICD-10-CA adaption
as developed by Quan et al. [23]. Originally, the inven-
ors refrained from introducing a summary score, as each
omorbidity may  affect outcomes differently depending
n the disease to that the instrument is applied to [22].
evertheless, van Walraven et al. introduced a summary
core to overcome the problem of overﬁtting in regressionolicy 105 (2012) 110– 118
models and the problem of not being able to provide an
overall description of a patient [24].
For some areas of disease, however, disease-speciﬁc
risk scores are available. The Ontario Acute Myocardial
Infarction Mortality Prediction Rules, a disease-speciﬁc
instrument for acute myocardial infarction (AMI), was
developed to predict 30-day and 1-year mortality after AMI
with inpatient administrative data. The instrument con-
tains 9 comorbidity groups, in addition to 3 categories for
age and a variable for gender [25]. The original ICD-9 codes
have been adapted to the ICD-10-CA version by Vermeulen
et al. [26].
As described above, a differentiation is to be made
between comprehensive risk adjustment instruments, e.g.
the Charlson Comorbidity Index or the Elixhauser Score,
and disease-speciﬁc risk adjustment instruments such as
the Ontario Myocardial Infarction Mortality Prediction
Rules. Regarding the two comprehensive risk adjustment
instruments, it has been noted that the Charlson Comor-
bidity Index concentrates more on chronic comorbidities at
the expense of acute illnesses [22]. This is in line with sev-
eral studies that compared both instruments concluding
that the Elixhauser performs better [27–29].
Whilst comprehensive risk adjustment instruments
have a broader spectrum of use, a validated disease-speciﬁc
risk adjustment instrument – if available – ought to be
preferred. This is because disease-speciﬁc risk adjustment
instruments are (a) usually much more clinically sensible
to the condition analysed, (b) have usually more predic-
tive power, and (c) allow for more degrees of freedom in
a regression framework due to lower number of variables
used [25]. However, it should be noted that for most condi-
tions there will be no disease-speciﬁc instrument available.
Still, the Ontario Acute Myocardial Infarction Mortality
Prediction Rules should be much more suitable for risk-
adjustment of a rare heart disease than any comprehensive
risk-adjustment instrument. If applied to rare diseases,
more attention should be paid to the number of variables
required to be entered into a regression model, as the num-
ber of observations is most likely to be low. Thus, the use of
summary scores might be preferable even though a recent
study with UK data showed that empirical weights out-
performed given weights for both Charlson and Elixhauser,
respectively [29].
In any case, coding for risk adjustment instruments as
supplied by numerous authors should be applied with cau-
tion, because comorbidity index codes (and weights) may
need to be adapted to national coding patterns. Whilst
differences between ICD-10 and the nationalised version
may  be small, they do nevertheless exist. For example, the
German ICD-10-GM (2009 version) includes a coding pos-
sibility for ‘diabetes with complications with the type of
complications not being speciﬁed’, i.e. E10.8, E11.8, etc. The
Canadian ICD-10-CA (2009 version) does not have these
codes for diabetes. Therefore E10.8, E11.8, E13.8, and E14.8
are not speciﬁed in the ICD-9 to ICD-10-CA adaption of the
Ontario AMI  mortality prediction rules provided by Ver-
meulen et al. [26]. Still, in an application of the Ontario
AMI  mortality prediction rules to German administrative
data, these coding differences would have to be considered
by researchers to avoid bias. For some versions crosswalks
Health PT. Stargardt, J. Schreyögg / 
between different ICD versions are available, e.g. by the
German Institute of Medical Documentation and Informa-
tion (DIMDI).
4. Statistical methods
In the ﬁnal step, appropriate statistical models have to
be selected for the two proposed research designs. First, the
evaluation of the effect of small area variations in health-
care infrastructure on early detection of disease requires
measurement of the time from the onset of the ﬁrst mea-
surable symptoms to the ﬁrst recorded diagnosis of the rare
disease. Second, the evaluation of the effect of small area
variations in healthcare infrastructure on health outcomes
requires measurement of the time to death for terminal
rare diseases after conﬁrmed diagnosis or the measure-
ment of outcome development over time after conﬁrmed
diagnosis. We  propose to analyse data in a multivariate
regression framework:
Outcome = f (vector of variables that describe the effect
of small area variations in healthcare infrastructure; vec-
tor of variables that describe patient characteristics and
patient comorbidities; vector of variables that control for
regional characteristics)
Model choice, however, depends on the distribution
of the outcome variables. As time to diagnosis, mortal-
ity, costs, or other outcomes of interest such as healthcare
utilization will in most cases not be normally distributed,
Ordinary Least Square (OLS) regression cannot usually
be applied. With respect to our ﬁrst research question
regarding delay in diagnosis, survival models seem to
be appropriate, provided that part of the data is cen-
sored, i.e. there are dropouts in the dataset. The choice
between Cox proportional hazard models and parametric
hazard models, e.g. Weibull, gamma  or generalised gamma
models, depends on whether the effect of covariates is
time-dependent (parametric model) or not (Cox propor-
tional hazard model). At the expense of time-independent
effects of covariates (proportionality assumption), the Cox-
proportional hazard models offer the advantage that no
assumption about the functional form of the underlying
baseline hazard has to be made [30,31] – in this case
the ‘hazard of being diagnosed’. Moreover, in the absence
of censored data, count-data models such as Poisson or
Negative-binomial regression, i.e. models for data with
nonnegative integers, can also be used. Another option is
the use of logistic regression on the binary outcome ‘imme-
diate diagnosis at the time of ﬁrst symptom yes/no’. All
three methods are also valid to analyse treatment out-
comes such as mortality.
For models with skewed, nonnegative continuous data,
either (a) the dependent variable may  be transformed by
the natural log and OLS regression can be performed, or
(b) a generalised linear model (GLM), e.g. with a gamma
distribution for the error term and a log link function,
is to be estimated. Because of retransformation bias for
natural logged dependent in an OLS regression, the GLM-
option should be preferred if predictions are the primary
aim [32,33].  More complex options include, for example,olicy 105 (2012) 110– 118 115
count data models, hazard models, or generalised estimat-
ing equations [34,35].  Ultimate model choice, however,
should always be determined based on best ﬁt. Raw-scaled
and log-scaled residuals should be plotted and compared as
well as likelihoods or likelihood based criteria such as the
Akaike information criterion (AIC) or the Bayesian informa-
tion criterion (BIC) [34].
If there are multiple observations in each area, mod-
els that ignore correlation among individuals that have
access to the same healthcare infrastructure will not yield
consistent estimates. Whilst age, comorbidities, and other
patient-related variables can differ for each treated patient,
variables on the health system level remain identical
for all patients treated in an area. As a result, multiple
observations within an area violate assumptions such as
independence and common variance. Signiﬁcance tests are
thus not robust and would overestimate the precision of
information provided by the system-level variables, i.e. P-
values would be too small [36,37]. To avoid this problem,
multilevel models are recommended. For survival out-
comes, random-effects proportional hazard models, also
known as frailty models, are recommended [38,39].  For
all other distributional characteristics generalised linear
mixed models provide a solution to this problem [40].
Where there is a low number of observations, standard
errors at least should be adjusted for correlation among
observations, e.g. by imposing a special structure on the
variance–covariance matrix. However, if the dataset is
large enough and degrees of freedom are sufﬁcient, a mul-
tilevel approach is preferable over a single level approach,
as the latter may  not fully exploit the information pro-
vided within and between the various levels [41]. Fig. 3
summarises the different steps of the proposed framework.
5. Policy implications
When drawing policy implications based on the use of
administrative data for the evaluation of small area varia-
tions on treatment of rare diseases, a number of points must
be considered. As always, the use of administrative data –
as opposed to primary data from randomised controlled tri-
als – has to be scrutinised with respect to its internal and
external validity. However, in the context of rare diseases
a number of other issues must be considered, principally
their rarity and variation in regional prevalence.
Internal validity is usually seen as the central weak-
ness of studies based on administrative data, as no ex-ante
randomization to provide homogenous groups can be
performed. The extent to which selection bias was con-
trolled for primarily determines internal validity [42]. Risk
adjustment through regression models and/or matching
methods, e.g. propensity score matching, perform a quasi
ex-post randomization and thus substantially reduce selec-
tion bias between two  groups, e.g. between two patient
populations from different areas [43]. Still, randomization
performed in RCTs will usually lead to higher internal valid-
ity, as regression models or matching methods condition on
observables and are therefore not able to remove selection
bias completely.
However, there is one serious threat for RCTs which
is seldom considered. Only sample sizes greater than 200
116 T. Stargardt, J. Schreyögg / Health Policy 105 (2012) 110– 118
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are likely to generate equivalent groups [44,45].  With
smaller sample sizes, randomization is often less effec-
tive in achieving proportional distributions of confounding
variables [46]. Thus, when the relative frequencies of a
known confounding variable are low for the strata of the
confounding variable, results may  lead to erroneous con-
clusions. This phenomenon is known as the Simpson’s
paradox [47]. For rare diseases it is often hard to recruit
more than 200 patients, even in multi-centre trials. Thus,
clinical studies on rare diseases are faced with the threat
that they may  be too small to avoid bias resulting from
the Simpson’s paradox. For rare diseases with a very low
prevalence, the use of administrative data from nationwide
NHS systems or sickness funds in SHI countries can be one
solution to the sample size problem.
In terms of external validity, the use of administrative
data is often seen as superior to primary data from RCTs
or clinical trials generally, as it more closely reﬂects the
real-world setting. Although this is certainly true for stud-
ies in the context of rare diseases, it has to be considered
that the prevalence of rare diseases is often much less uni-
formly distributed among populations within and between
healthcare systems than is the case for common diseases
such as Diabetes. For instance some rare diseases are due
to genetic inheritance and therefore immigrants may  be
more affected than others. If immigrants are concentrated
in a few small areas in one healthcare system, generaliza-
tion to other regions regarding requirements of healthcare
infrastructure has to be approached with caution. Thus,
distribution of rare diseases among populations should be
considered in research models for the evaluation of health-
care system effects on treatment of rare diseases.
Health researchers may  use this framework as step
by step guidance for research on small area variations in
healthcare infrastructure in the context of rare diseases.
In particular, Fig. 3 can be used as a checklist when plan-
ning the study design and getting started with a research
project. Therefore, this article may  facilitate studies inves-
tigating small area variation in providing care for patients
with rare diseases. Subsections, e.g. identiﬁcation of dis-
eases or risk-adjustment, may  also be relevant when doing
research in related areas, in particular, when working with
administrative data overall.
Finally, health policy implications from studies on small
area variations have to be drawn with great care. Studies
on small area variations and its resulting effects primarily
serve as a positive analysis, revealing differences in patient
care without, however, suggesting direct policy implica-
tions [48]. Also, policy decisions will need to be based
on evidence from multiple sources, e.g. RCTs, retrospec-
tive or prospective observational studies, and qualitative
studies. These different approaches will provide different
types of evidence, and are complementary rather than sub-
stitutes. National disease registries with mandatory data
submission could provide an alternative to rely solely on
administrative data when analysing rare diseases.
Given the proposed framework for evaluation in the
context of rare diseases, it would be misleading to conclude
simply that denser healthcare infrastructure is needed in
areas with longer time to diagnosis or worse outcomes.
There may  be many other ways to reduce the differences
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that may  be identiﬁed in time to diagnosis and treatment
outcomes for rare diseases. Such further solutions may
include establishing specialty centres for rare diseases in
larger hospitals, increasing the mobility of patients with
rare diseases, and enforcing the training of doctors to diag-
nose and treat rare diseases.
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